{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lopez J"],"funding":["Square Foundation","Claude Bernard Lyon 1 University","French Foundation for Medical Research","NCATS NIH HHS","Agence Nationale de la Recherche","Howard Hughes Medical Institute","George Mason University","Fondation des Hospices Civils de Lyon","National Institutes of Health","JPB Foundation","St. Giles Foundation","REACTing","SCOR Corporate Foundation for Science","Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence","Centre National de la Recherche Scientifique","Fisher Center for Alzheimer's Research Foundation","NIH HHS","National Center for Advancing Translational Sciences","Institut Mérieux","Grandir - Fonds de solidarité pour l'enfance","Grandir - Fonds de solidarité pour l’enfance","NIAID NIH HHS","Institut National de la Santé et de la Recherche Médicale","Fisher Center for Alzheimer’s Research Foundation","Emergent Ventures","Institut National du Cancer","École normale supérieure de Lyon","Fondation ARC","Fondation ARC (équipe labellisée)","Meyer Foundation","Rockefeller University","Hospices Civils de Lyon","University of Paris"],"pagination":["e20211211"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8352718"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["218(10)"],"pubmed_abstract":["IFN-I and IFN-III immunity in the nasal mucosa is poorly characterized during SARS-CoV-2 infection. We analyze the nasal IFN-I/III signature, namely the expression of ISGF-3-dependent IFN-stimulated genes, in mildly symptomatic COVID-19 patients and show its correlation with serum IFN-α2 levels, which peak at symptom onset and return to baseline from day 10 onward. Moreover, the nasal IFN-I/III signature correlates with the nasopharyngeal viral load and is associated with the presence of infectious viruses. By contrast, we observe low nasal IFN-I/III scores despite high nasal viral loads in a subset of critically ill COVID-19 patients, which correlates with the presence of autoantibodies (auto-Abs) against IFN-I in both blood and nasopharyngeal mucosa. In addition, functional assays in a r"],"journal":["The Journal of experimental medicine"],"pubmed_title":["Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs."],"pmcid":["PMC8352718"],"funding_grant_id":["ANR-20-C11-0001","ANRS-COV05","R01AI088364","R01 AI088364","ANR-10-LABX-62-IBEID","UL1 TR001866","ANR-20-COVI-0003","EQU201903007798","ANR-10-IAHU-01"],"pubmed_authors":["Padey B","Rosa-Calatrava M","Bal A","Bastard P","Morfin F","Duliere V","Cheynet V","Paul S","Casanova JL","Mezidi M","Richard JC","Walzer T","Pizzorno A","Brengel-Pesce K","Lopez J","Belot A","Mommert M","Trouillet-Assant S","Julien T","Lina B","Fassier JB","Mouton W","Villard M"],"additional_accession":[]},"is_claimable":false,"name":"Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs.","description":"IFN-I and IFN-III immunity in the nasal mucosa is poorly characterized during SARS-CoV-2 infection. We analyze the nasal IFN-I/III signature, namely the expression of ISGF-3-dependent IFN-stimulated genes, in mildly symptomatic COVID-19 patients and show its correlation with serum IFN-α2 levels, which peak at symptom onset and return to baseline from day 10 onward. Moreover, the nasal IFN-I/III signature correlates with the nasopharyngeal viral load and is associated with the presence of infectious viruses. By contrast, we observe low nasal IFN-I/III scores despite high nasal viral loads in a subset of critically ill COVID-19 patients, which correlates with the presence of autoantibodies (auto-Abs) against IFN-I in both blood and nasopharyngeal mucosa. In addition, functional assays in a r","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2026-05-31T18:02:45.822Z","creation":"2025-04-05T22:20:51.669Z"},"accession":"S-EPMC8352718","cross_references":{"pubmed":["34357402"],"doi":["10.1084/jem.20211211"]}}